News Center

News Center

Shengshi Taikang's Class 1 innovative drug, phosphate senglitagliptin, enters Phase I clinical trials.

Release date:

2017-09-15

China is a global leader in diabetes, currently home to over 100 million people living with the condition. In May 2017, Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. received approval from the National Medical Products Administration to initiate clinical trials for its Class 1 innovative drug, phosphate sengliflozin, intended for the treatment of type 2 diabetes. Currently, Shengshi Taikang has partnered with institutions such as Jiangsu Provincial People’s Hospital to conduct Phase I clinical trials of phosphate sengliflozin. As a DPP-4 inhibitor, this drug stands out for its ability to avoid hypoglycemia and weight gain, while also offering cardiovascular protective benefits. Moreover, given that Chinese patients with type 2 diabetes often experience more severe damage to their pancreatic β-cells compared to patients in Europe and North America—yet DPP-4 inhibitors are particularly effective in improving β-cell function—Chinese patients stand to benefit even more from this class of medications. This unique advantage has increasingly earned DPP-4 inhibitors greater recognition and acceptance among physicians in China.

Phosphate Sengliflozin is a major new drug development project under China’s 12th Five-Year Plan and Jiangsu Province’s “Science and Technology Support Program”—a wholly independently developed novel treatment for diabetes. Preclinical studies of Phosphate Sengliflozin have demonstrated that its efficacy is 3 to 10 times greater than that of the globally leading drug, Phosphate Sitagliptin (Januvia), while its safety profile is more than 5 times superior. These advantages are remarkably clear-cut. The successful launch of Phosphate Sengliflozin will provide hundreds of millions of Chinese type 2 diabetes patients with a more affordable, safer, and highly effective treatment option, further elevating the standard of care for type 2 diabetes in China. Shengshi Taikang will continue to prioritize independent innovation as the driving force behind our company’s growth, steadfastly upholding our mission to develop groundbreaking therapies for China’s most pressing health challenges. We will maintain close collaboration with academic institutions both domestically and internationally, actively pioneering the path toward industrializing China’s pharmaceutical and biotech innovations—ultimately benefiting countless patients across the country.

Prev：

Shengshi Taikang Announces Completion of Nearly 100 Million RMB in Series A Funding on "Double 12"

Next：

No

中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地